Characterizing Dual Combination Therapy Use in Treatment Escalation of Hypertension: Real-World Evidence from Multinational Cohorts

Yuan Lu, Jing Li, Xialin Wang, Jaehyeong Cho, Sreemanee Raaj Dorajoo, Mengling Feng, Min‐Huei Hsu, Jason C. Hsu, Hwang Jiyoun, Usman Iqbal, Chen Zhengfeng Jason, Jitendra Jonnagaddala, Yu‐Chuan Li, Siaw-Teng Liaw, Hong‐Seok Lim, Kee Yuan Ngiam, Phung‐Anh Nguyen, Rae Woong Park, Nicole Pratt, Christian Reich, Sang Youl Rhee, Selva Muthu Kumaran Sathappan, Seo Jeong Shin, Hui Xing Tan, Seng Chan You, Xin Zhang, Harlan M. Krumholz, Marc A. Suchard, Yun Liu, Mui Van Zandt, Hua XuSSRN 2021 · DOI

Introduction

Hypertension remains a primary driver of global cardiovascular morbidity and mortality, affecting over one billion people worldwide. While clinical guidelines provide clear frameworks for initiating treatment, the path forward becomes significantly less certain when a single medication (monotherapy) fails to achieve blood pressure targets. Approximately 70% of patients eventually require treatment escalation to dual combination therapy. However, due to a lack of head-to-head clinical trials comparing different drug combinations, there is no global consensus on the optimal second-line therapy. This study characterizes real-world prescribing patterns across diverse multinational cohorts to understand how clinicians navigate this transition.

Methodology: Leveraging Global Real-World Data

To map these prescribing patterns, researchers utilized the Observational Health Data Science and Informatics (OHDSI) collaborative network. This "open science" framework allows for the execution of standardized analytical code across disparate international databases while ensuring patient data remains secure within its home institution.

Study Design and Data Standardization

  • OMOP Common Data Model: Data from 11 different electronic health record (EHR) databases were standardized into a single format to ensure cross-institutional compatibility.
  • New-User Cohort Design: To minimize selection bias and mimic the structure of a Randomized Controlled Trial (RCT), the study focused on "new users"—patients who were stable on a single drug class before adding a second.
  • Exposure Cohorts: The researchers tracked transitions between the four major antihypertensive drug classes: ACE inhibitors/ARBs, Calcium Channel Blockers (CCBs), Beta-blockers, and Diuretics, resulting in 12 non-overlapping exposure cohorts.

Dataset Scope

The study drew from a massive initial pool of 118 million patients across 11 databases in eight countries and regions, including the United States, Australia, France, Italy, China, Singapore, South Korea, and Taiwan. From this pool, 980,648 patients met the rigorous criteria for inclusion in the treatment escalation analysis.

Results: A Map of Global Variation

The most significant finding of the study was the profound geographic variation in prescribing habits, suggesting that treatment escalation is often dictated by regional norms rather than a unified biological standard of care.

Regional Prescribing Clusters

The study identified distinct "clusters" of clinical practice:

  • The Diuretic Path: In the United States, France, and Italy, the most common escalation strategy involved adding a diuretic to an existing ACEi/ARB monotherapy, occurring in approximately 25–28% of cases.
  • The CCB Path (Western): In Australia and Singapore, the preferred move was the addition of a CCB to an ACEi/ARB regimen.
  • The CCB Path (East Asian): In South Korea, China, and Taiwan, the pattern was often reversed; patients frequently began on a CCB and subsequently added an ACEi/ARB.
  • Least Utilized Combinations: Across all regions, combinations involving both Beta-blockers and diuretics were among the least frequently prescribed, often representing less than 1.2% of the study population.

Demographic and Clinical Influences

Beyond geography, patient characteristics played a significant role in drug selection:

  • Gender and Age: Women were significantly more likely to be prescribed diuretics than men, while younger patients were more frequently escalated using ACEi/ARBs.
  • Comorbidities: Patients with a documented history of cardiovascular disease (CVD) were much more likely to receive Beta-blockers, likely reflecting adherence to secondary prevention guidelines for heart disease.

Discussion: The "Trial-and-Error" Reality

The high degree of variation observed suggests that in the absence of high-quality comparative evidence, clinical practice is driven by a combination of local guidelines, drug availability, cost, and historical prescribing habits. This "trial-and-error" approach highlights a critical gap in hypertension management: the need for evidence-based clarity on which dual-therapy combinations yield the best long-term outcomes.

Limitations and Future Directions

While this study provides an unprecedented look at global prescribing, it is subject to the limitations of real-world data. EHR data relies on accurate clinical coding, and prescription records do not necessarily guarantee patient adherence. Furthermore, the study's focus on eight countries may not fully represent prescribing patterns in low-income regions or other continents such as Africa and South America.

This descriptive analysis serves as a vital first step for the OHDSI community. The next phase of research must move from characterizing what is being prescribed to determining which combinations are most effective. Large-scale comparative effectiveness research is required to identify which of these common real-world strategies best reduces the incidence of major adverse cardiovascular events, such as myocardial infarction and stroke.

Summary updated

BibTeX
@misc{lu2021characterizing,
  author = {Yuan Lu and Jing Li and Xialin Wang and Jaehyeong Cho and Sreemanee Raaj Dorajoo and Mengling Feng and Min‐Huei Hsu and Jason C. Hsu and Hwang Jiyoun and Usman Iqbal and Chen Zhengfeng Jason and Jitendra Jonnagaddala and Yu‐Chuan Li and Siaw-Teng Liaw and Hong‐Seok Lim and Kee Yuan Ngiam and Phung‐Anh Nguyen and Rae Woong Park and Nicole Pratt and Christian Reich and Sang Youl Rhee and Selva Muthu Kumaran Sathappan and Seo Jeong Shin and Hui Xing Tan and Seng Chan You and Xin Zhang and Harlan M. Krumholz and Marc A. Suchard and Yun Liu and Mui Van Zandt and Hua Xu},
  title = {{Characterizing Dual Combination Therapy Use in Treatment Escalation of Hypertension: Real-World Evidence from Multinational Cohorts}},
  year = {2021},
  doi = {10.2139/ssrn.3885636},
  howpublished = {SSRN},
}
Figure